Sisram Medical Announces Share Repurchase Plan

HONG KONG, Oct. 8, 2026 /CourierPR/ -- Sisram Medical Ltd, a global wellness group with a 25-year history in Energy-Based Devices (EBD), injectables, and other complementary solutions, has announced a share repurchase plan. The company aims to repurchase up to 1% of its issued shares, reflecting the Board of Directors' and management's confidence in the company's long-term prospects and commitment to shareholder returns.

The share repurchase plan is part of Sisram's ongoing strategy to enhance shareholder value.

In the first half of 2026, Sisram delivered steady business progress, with revenue reaching US$171.4 million, up 3.6% year on year. Revenue from international markets (excluding North America) rose 16.7% YoY to US$127.0 million. APAC stood out as a key driver of international growth, generating US$78.4 million in revenue, an increase of 19.1% YoY. The injectables business maintained robust momentum, with revenue rising 54.2% YoY to US$22.2 million and accounting for 12.9% of total revenue, cementing its position as the Company's second growth engine.

Operational momentum was evident across Sisram's core businesses. In the EBD business, flagship platforms including Alma Harmony and Hybrid family sustained solid market traction, while new product rollouts across APAC and localization initiatives in China advanced in tandem. In the injectables business, the commercialization of DAXXIFY in mainland China progressed steadily, while differentiated products including Profhilo and Hallura broadened their presence, further strengthening the foundation for more diversified growth.

Sisram Medical Ltd, listed on the Main Board of the Hong Kong Stock Exchange since September 2017, is a global leader in medical aesthetic solutions. The company serves customers in over 110 countries and regions, delivering award-winning products that set new standards in safety, efficacy, and personalized aesthetic care for millions of patients worldwide. Majority-owned by Fosun Pharma, Sisram continues to advance the iteration of its core products and the translation of innovation into commercial outcomes, while accelerating the registration and commercialization of key products across major global markets.

Looking ahead, Sisram will further strengthen the strategic integration of R&D and innovation, global commercial operations, and localized capabilities, anchored by its three global strategic hubs in Israel, the United States, and China. The Company will continue to explore partnerships and strategic growth opportunities that create meaningful synergies with its broader wellness ecosystem. Through a more resilient global operating platform and increasingly diversified growth drivers, Sisram aims to build a solid foundation for sustainable long-term growth.